Baseline Productions

Baseline Productions EV/EBITDA

The EV/EBITDA (Enterprise Value to EBITDA) of Baseline Productions (BSSP) as of Nov 15, 2026 is -1.11.

EV/EBITDA

-1.11

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Baseline Productions is 2014 -1.11 . EV/EBITDA (Enterprise Value to EBITDA) of Baseline Productions was 2013 - . It decreases by % lower compared to the previous year.

The Baseline Productions EV/EBITDA history

The Baseline Productions EV/EBITDA history
YEAREV/EBITDAYoY
-1.11—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baseline Productions Stock analysis

What does Baseline Productions do? Baseline Productions Inc develops mobile based hardware and software based products. The company focuses on commercialization of its proteins for cancer and infectious disease treatments. Its Irreversible Pepsin Fraction (IPF) technology activates the immune system to fight autoimmune diseases. IPF binds to T-cells and triggers Th1 responses that eliminate infected cells. The firm's lead compound is an IPF suspension for autoimmune disease treatment including cancer, cirrhosis, and Hepatitis C. The product IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein derived from porcine pepsin, which is irreversible, modified, and fractionated to IPF sequence. The company sells its IPF platform technology and ITP product to healthcare providers and pharmaceutical companies. Healthcare providers use IPF for immune system activation in autoimmune disease treatment. Pharmaceutical companies purchase ITP for development into therapeutic applications. The target segments include medical institutions treating autoimmune conditions and drug manufacturers seeking novel protein-based therapies. ITP is specifically indicated for cancer, cirrhosis, and Hepatitis C treatment. Baseline Productions generates revenue through licensing IPF technology and selling ITP therapeutic protein. The IPF platform is sold as a technology solution to partners in the healthcare sector. ITP is marketed as a therapeutic product for direct sale to medical facilities. The company's primary customers are healthcare institutions and pharmaceutical firms interested in immune system-based treatments for autoimmune diseases and infectious conditions. Baseline Productions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baseline Productions stock

EV/EBITDA (Enterprise Value to EBITDA) of Baseline Productions is -1.11 in 2014.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Baseline Productions since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Baseline Productions with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Baseline Productions

All Key Metrics — Baseline Productions